Technavio Analyses Top Four Emerging Trends Impacting the Infectious Disease Testing Market in the US Through 2019

LONDON--()--Technavio’s latest report on the infectious disease testing market in the US 2015-2019 provides an analysis on the most important trends expected to impact the market outlook through 2019. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

Technavio’s research analysts have identified and analysed the top four emerging trends in the infectious disease testing market in the US from 2015-2019. They are as follows:

Development of innovative diagnostics initiatives

According to the new market research report by Technavio, The United Nations Development Programme, World Bank, World Health Organization (WHO), and Bill and Melinda Gates Foundation are focusing on developing innovative diagnostic tests for deadly diseases. In September 2014, the Bill and Melinda Gates Foundation donated $50 million to scale up emergency efforts during the Ebola outbreak.

The Foundation for Innovative New Diagnostics (FIND), a not-for-profit foundation that focuses on TB, collaborated with WHO to develop new and affordable products by applying latest innovations in technology. The foundation signed a five-year memorandum in July 2015 with Qiagen to speed up the development and evaluation of new tests for the detection of TB. The partners will work together for the development of new tests; FIND will provide access to its Biobank of TB specimens to Qiagen to develop diagnostics for treating the disease. QuaniFERON-TB Gold Plus is one of the specific product Qiagen offers for TB. Such initiatives taken by different organizations is likely to boost the infectious disease testing market in the US over the next four years.

Key role of US Army Medical Research Institute in Diagnostics and Development (USAMRIID)

Technavio’s report also highlights the research organized by USAMRIID to develop diagnostics, drugs, and vaccines for infectious diseases to protect the members of the military from biological threats. The Department of Defence has an acquisition program, which includes design, engineering, test evaluation, production, operation, and support of defence systems.

The Biomedical Advanced Research and Development Authority (BARDA) under the US Department of Health and Human Services provides funding for the development and purchase of vaccines for infectious diseases. The BARDA recently funded projects related to Ebola.

Low-cost microfluidic devices for point-of-care testing (POCT)

The report also focuses on the new evolving technologies like nano or microfluidic technologies that are emerging as a powerful tool to detect, diagnose, and monitor infectious diseases. The miniaturized microfluidic platforms are used for small fluid volumes to provide a rapid and accurate diagnosis. Development of paper-based microfluidic devices using the fast lithographic activation of sheets (FLASH) technology is making it less expensive, disposable, and useful for on-chip processes.

Technavio’s lead research analysts, Brahadeesh Chandrasekaran says, “SurModics has incorporated FLASH technology in its in vitro diagnostics products such as Codelink Microarray slides, Microarray stabilizers, and TRIDIA Surfaces.”

Focus on early diagnosis of infectious diseases

The research study also reports that the early diagnosis of infectious diseases helps avert severe or fatal complications associated with infections. Early diagnosis also helps in better planning of the treatment regimen, reduces the recovery time and healthcare expenditure significantly. “These advantages of infectious disease diagnostic devices is expected to boost the market growth in the coming years. For instance, Alere BinaxNOW Influenza A&B Card can detect influenza A and B infections in just 15 minutes,” says Brahadeesh Chandrasekaran, Technavio’s lead research analyst.

Browse Related Reports:

Purchase these three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact enquiry@technavio.com with your requirements and a link to our subscription platform.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630-333-9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio’s latest report on the infectious disease testing market in the US 2015-2019 provides an analysis on the most important trends expected to impact the market outlook through 2019.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630-333-9501
UK: +44 208 123 1770
www.technavio.com